Efavirenz Metabolism and CNS Toxicity in Ugandan Children: CYP2B6 Genotype Impact

A prospective study of 99 Ugandan children aged 3-12 years initiating efavirenz-based HIV therapy in 2015-2016. The dataset likely contains plasma concentrations of efavirenz and its metabolites, CYP2B6/CYP2A6 genotypes, and CNS adverse effect assessments collected over 24 weeks. It was authored by Sandra Soeria-Atmadja and shared under a CC-BY-4.0 license.

Use Cases

• Modeling the association between CYP2B6 metabolizer phenotype and plasma metabolite ratios based on genotyping data.
• Investigating the link between high efavirenz plasma concentrations (>4,000 ng/mL) and central nervous system toxicity symptoms.
• Studying the autoinduction of efavirenz metabolism over time in extensive metabolizers.
• Analyzing the distribution patterns of conjugated versus unconjugated drug metabolites across different metabolizer phenotypes.

Strengths

• Includes data from 99 pediatric patients, a specific and often understudied population.
• Longitudinal design with plasma sampling at four time points over 24 weeks.
• Quantifies multiple efavirenz metabolites, including conjugated forms and a recently identified metabolite (EFAdeg).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 38.2 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Prospective clinical study using liquid chromatography high-resolution tandem mass spectrometry for quantification and genotyping for SNPs.

Time Range

2015-2016

Freshness

Last updated 2026-04-24 05:40:41; freshness should be verified.

Geography

Uganda